Appendix 3Y Change of Director’s Interest Notice

CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to the sale of shares held directly by Managing Director, Dr Philippe Wolgen.

The Company wishes to advise that the sale, which comprises approximately 2.9% of the total number of shares held directly or indirectly by Dr Wolgen, was undertaken to meet personal commitments.

In an open trading period, following the release of the financial results for the six-months ended 31 December 2020, Dr Wolgen sold 104,000 shares on the open market. The 104,000 shares sold represents the number of ordinary shares the executive has previously purchased on the open market during his time as a director of the company.

Dr Wolgen remains a substantial shareholder in the Company.

– End –

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Download PDF

Appendix 3Y
Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of Entity:	CLINUVEL PHARMACEUTICALS LTD
ABN:	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	01 September 2020

Part 1 – Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	03 March 2021
No. of securities held prior to change	3,504,696 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights
Class	Ordinary Shares
Number acquired	nil
Number disposed	104,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$2,564,744.00
No. of securities held after change	3,400,696 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights (various milestones, expiry date 20/11/2023)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	On-market purchase

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 – Closed Period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A